共 53 条
[1]
Drucker D.J., Nauck M.A., The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes, Lancet, 368, pp. 1696-1705, (2006)
[2]
Dunning B.E., Foley J., Ahren B., Alpha-cell function in health and disease: Influence of GLP-1, Diabetologia, 48, pp. 1700-1713, (2005)
[3]
Nauck M.A., Niedereichholz U., Ettler R., Et al., Glucagon-like peptide-1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans, Am J Physiol, 6, (1997)
[4]
Gutzwiller J.P., Drewe J., Boke B., Et al., Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2, Am J Physiol, 276, (1999)
[5]
Perfetti R., Hui H., The role of GLP-1 in the life and death of pancreatic beta cells, Horm Metab Res, 36, pp. 804-810, (2004)
[6]
Ahren B., Schmitz O., GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes, Horm Metab Res, 36, pp. 867-887, (2004)
[7]
Meier J.J., Nauck M.A., GIP as a potential therapeutic agent?, Horm Metab Res, 36, pp. 859-866, (2004)
[8]
Gutniak M., Orskov C., Hoist J.J., Et al., Antidiabetic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus, N Engl J Med, 326, pp. 1316-1322, (1992)
[9]
Zander M., Madsbad S., Madsen J.L., Holst J.J., Effect of 6-week course of glucagon-like peptide I on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study, Lancet, 359, pp. 824-830, (2002)
[10]
Mentlein R., Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides, Regul Pept, 85, pp. 9-24, (1999)